WINDLAS BIOTECH
|
The Current P/E Ratio of WINDLAS BIOTECH is 25.55.
| Share Price | ₹815.2 | Nov 19,2025 |
| Market Cap | ₹1,720.0 Cr | |
| Earnings-TTM | ₹67.3 Cr | TTM-Consolidated Results |
| Price/Earnings | 25.55x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of WINDLAS BIOTECH
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,720.0 Cr] as on Nov 19,2025
(/) Earnings [ ₹67.3 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 25.55x ]
Thus, for WINDLAS BIOTECH , the investors are currently willing to pay 25.55 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of WINDLAS BIOTECH !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of WINDLAS BIOTECH over the last five years.
Historical PE (Price/Earnings) ratio chart of WINDLAS BIOTECH
PE Ratio Performance Analysis for WINDLAS BIOTECH
- WINDLAS BIOTECH 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 15.43x.
- WINDLAS BIOTECH 's operated at median p/e ratio of 12.02x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, WINDLAS BIOTECH 's p/e ratio peaked in Mar2025 at 35.78x.
- WINDLAS BIOTECH 's p/e ratio hit its five-year low in Mar2021 of 0x.
How does WINDLAS BIOTECH 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| WINDLAS BIOTECH | 67.32 | 25.55 | 1,720.0 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 40.70 | 428,077.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 68.94 | 171,324.0 |
| CIPLA LTD | 5,453.86 | 22.61 | 123,294.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 58.99 | 126,235.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 18.24 | 104,336.0 |
| MANKIND PHARMA LTD | 1,767.06 | 51.93 | 91,762.4 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 18.82 | 93,620.0 |
| LUPIN LTD | 4,347.53 | 21.28 | 92,501.2 |
| AUROBINDO PHARMA LTD | 3,447.75 | 20.77 | 71,609.9 |
| ABBOTT INDIA LTD | 1,508.95 | 41.65 | 62,855.2 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs WINDLAS BIOTECH 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.24x |
| Max industry PE | 68.94x |
| Median industry PE | 25.55x |
| Average industry PE | 35.41x |
You may also like the below Video Courses